GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atrion Corp (NAS:ATRI) » Definitions » ROE %
中文

Atrion (Atrion) ROE % : 10.64% (As of Dec. 2023)


View and export this data going back to 1972. Start your Free Trial

Atrion ROE % Definition

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Atrion's annualized net income for the quarter that ended in Dec. 2023 was $25.7 Mil. Atrion's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $241.5 Mil. Therefore, Atrion's annualized ROE % for the quarter that ended in Dec. 2023 was 10.64%.

The historical rank and industry rank for Atrion's ROE % or its related term are showing as below:

ATRI' s ROE % Range Over the Past 10 Years
Min: 8.05   Med: 16.87   Max: 21.07
Current: 8.07

During the past 13 years, Atrion's highest ROE % was 21.07%. The lowest was 8.05%. And the median was 16.87%.

ATRI's ROE % is ranked better than
67.45% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.29 vs ATRI: 8.07

Atrion ROE % Historical Data

The historical data trend for Atrion's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atrion ROE % Chart

Atrion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.39 13.43 13.64 14.47 8.05

Atrion Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.70 5.83 10.95 4.89 10.64

Competitive Comparison of Atrion's ROE %

For the Medical Instruments & Supplies subindustry, Atrion's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atrion ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Atrion's ROE % distribution charts can be found below:

* The bar in red indicates where Atrion's ROE % falls into.



Atrion ROE % Calculation

Atrion's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=19.411/( (239.541+242.889)/ 2 )
=19.411/241.215
=8.05 %

Atrion's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=25.696/( (240.182+242.889)/ 2 )
=25.696/241.5355
=10.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Atrion  (NAS:ATRI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=25.696/241.5355
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(25.696 / 174.336)*(174.336 / 262.817)*(262.817 / 241.5355)
=Net Margin %*Asset Turnover*Equity Multiplier
=14.74 %*0.6633*1.0881
=ROA %*Equity Multiplier
=9.78 %*1.0881
=10.64 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=25.696/241.5355
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (25.696 / 29.052) * (29.052 / 26.656) * (26.656 / 174.336) * (174.336 / 262.817) * (262.817 / 241.5355)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8845 * 1.0899 * 15.29 % * 0.6633 * 1.0881
=10.64 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Atrion ROE % Related Terms

Thank you for viewing the detailed overview of Atrion's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Atrion (Atrion) Business Description

Traded in Other Exchanges
N/A
Address
One Allentown Parkway, Allen, TX, USA, 75002-4211
Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.
Executives
Preston G Athey director ONE ALLENTOWN PKWY, ALLEN TX 75002
David A Battat officer: President & CEO 2700 HALKEY-ROBERTS PLACE NORTH, ST. PETERSBURG FL 33716-4103
Jeannette Bankes director ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Morgan Hugh J Jr director
Ronald Nicholas Spaulding director ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Cindy Ferguson officer: Officer/ CFO ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffery Strickland officer: Vice President & CFO
Emile A Battat director, officer: Chairman ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Stupp John P Jr director STUPP JOHN P JR, #18 ST. ANDREWS DR., ST LOUIS MO 63124
Roger F Stebbing director
Ronald N Spaulding director C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Richard O Jacobson director ONE ALLENTOWN PARKWAY, C/O ATRION, ALLEN TX 75002
Maley John H P director 6 ROCK CREST LANE, SIGNAL MOUNTAIN TN 37377
Margaret Maxwell Zagel director C/O TELLABS OPERATIONS INC, 4951 INDIANA AVE, LISLE IL 60532

Atrion (Atrion) Headlines

From GuruFocus

Atrion Corporation Declares Quarterly Cash Dividend

By GuruFocusNews GuruFocusNews 07-03-2022

Atrion Corporation Increases Quarterly Cash Dividend by 10%

By GlobeNewswire GlobeNewswire 08-22-2022

Atrion Corporation Declares Quarterly Cash Dividend

By GuruFocusNews GuruFocusNews 06-13-2022

Atrion Reports First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 05-29-2022

Atrion Corporation Declares Quarterly Cash Dividend

By Don Li2 Don Li2 11-12-2021

Atrion Reports First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 06-18-2022

Atrion Reports Third Quarter 2022 Results

By Value_Insider Value_Insider 11-08-2022

Atrion Reports First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 06-08-2022